Skip to main content
Algernon Health Inc. logo

Algernon Health Inc. — Investor Relations & Filings

Ticker · AGN ISIN · CA3978841078 CSE Human health and social work activities
Open in API
Filings indexed 579 across all filing types
Latest filing 2022-07-07 Regulatory Filings
Country CA Canada
Listing CSE AGN

About Algernon Health Inc.

https://www.algernonhealth.com/

Algernon Health Inc. is a healthcare company focused on the provision of advanced diagnostic services, primarily through the establishment of medical clinics specializing in Alzheimer's disease. A key offering is the utilization of brain-optimized Positron Emission Tomography (PET) scanning technology for screening and imaging within a planned network of North American facilities. The company maintains a clinical-stage drug development and repurposing division, which investigates existing, approved drugs for new therapeutic applications targeting unmet global medical needs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release dated July 7, 2022, from Algernon Pharmaceuticals providing an update on its Phase 1 clinical study of DMT for stroke. It discusses the study design, regulatory filings with the UK MHRA, and operational details about the clinical trial preparation. There are no financial statements, earnings data, or detailed financial analysis. The document is informational about clinical trial progress and regulatory interactions, typical of a corporate announcement or update. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings related to financial compliance. It is not a report publication announcement since it does not mention the release or availability of a formal report. The content is best classified as a Regulatory Filings (RNS) type, as it is a general regulatory announcement and update that does not fit other specific categories.
2022-07-07 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Algernon Pharmaceuticals disclosing a novel patent strategy related to new salt forms of DMT. It discusses intellectual property filings, preclinical study results, and the company's strategy around patenting. There is no financial data, regulatory filing, or report attached or referenced as being published. The content is primarily an announcement about intellectual property and patent strategy, not a financial report, earnings release, or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a management or board announcement, nor a voting or dividend announcement. The document is best classified as a general regulatory announcement or miscellaneous corporate news that does not fit other categories, which corresponds to Regulatory Filings (RNS).
2022-07-05 English
Other.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing an update on the acquisition progress of the Kalahari Palladium-Platinum Project by Glacier Lake Resources Inc. It discusses the status of the transaction, conditions to completion, financing plans, and regulatory approvals needed. There are no financial statements, detailed financial data, or comprehensive report content. The document is an announcement about a capital transaction and financing update rather than a full report or detailed financial disclosure. It fits the category of Capital/Financing Update (CAP) as it provides information on the progress of a financing and acquisition transaction.
2022-07-05 English
Other.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'Warrant Indenture Providing for the Issue of Warrants' and is dated July 4, 2022. It is a detailed legal agreement between Algernon Pharmaceuticals Inc. and TSX Trust Company acting as the Warrant Agent. The content includes definitions, terms of warrants, exercise rights, adjustments, enforcement, meetings of warrantholders, and other legal provisions related to the issuance and management of warrants. This is a formal legal contract governing the issuance and administration of warrants, which are financial instruments related to capital raising. It is not a financial report, earnings release, management discussion, or regulatory filing in the usual sense. It is also not an announcement or summary but the full indenture document itself. Given the nature of the document as a legal contract related to capital instruments, the most appropriate classification is 'Capital/Financing Update' (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is substantive and lengthy (15,000 characters), so it is not merely an announcement or notice. Therefore, the classification is CAP with high confidence.
2022-07-05 English
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a Form 51-102F3 Material Change Report filed by Algernon Pharmaceuticals Inc. It details a material change event, specifically the completion of a marketed public offering of units, including the number of units issued, pricing, warrant details, and use of proceeds. The document is a regulatory filing reporting a financing event but is not a full financial report or earnings release. It is not a report publication announcement since it contains substantive details of the transaction. The content aligns with updates on company fundraising and capital structure changes, which fits the Capital/Financing Update category (CAP). The document length is 4242 characters, which is concise but contains full details of the financing event, not just an announcement or summary. Therefore, the best classification is Capital/Financing Update (CAP).
2022-07-04 English
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a Form 51-102F3 Material Change Report filed by Algernon Pharmaceuticals Inc. It details a material change event, specifically the completion of a marketed public offering of units, including the number of units issued, pricing, warrant details, and use of proceeds. The document is a regulatory filing reporting a significant corporate event related to financing but is not a full financial report or earnings release. It is not an announcement of a report publication but the actual material change report itself. This fits the category of Capital/Financing Update (CAP) as it provides detailed information on a financing transaction and capital structure change.
2022-07-04 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.